MX2009013019A - Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica. - Google Patents
Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica.Info
- Publication number
- MX2009013019A MX2009013019A MX2009013019A MX2009013019A MX2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A MX 2009013019 A MX2009013019 A MX 2009013019A
- Authority
- MX
- Mexico
- Prior art keywords
- suspensions
- drug release
- resin systems
- ionic resin
- modifying drug
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
- A61K47/585—Ion exchange resins, e.g. polystyrene sulfonic acid resin
Abstract
La presente invenci?n incluye composiciones y m?todos para suministrar una o m?s unidades de dosificaci?n unitaria mediante la modificaci?n del perfil de liberaci?n de un complejo de resina de f?rmaco opcionalmente recubierto, suspendido en una soluci?n de sal i?nica, en donde el complejo de resina de f?rmaco opcionalmente recubierto incluye uno o m?s agentes activos cargados en una o m?s part?culas de resina de intercambio de iones y en donde la liberaci?n de uno o m?s agentes activos es modulada por una o m?s sales i?nicas en soluci?n.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US94095607P | 2007-05-30 | 2007-05-30 | |
PCT/US2008/065408 WO2008151071A1 (en) | 2007-05-30 | 2008-05-30 | Modifying drug release in suspensions of ionic resin systems |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2009013019A true MX2009013019A (es) | 2010-04-01 |
Family
ID=40094143
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2009013019A MX2009013019A (es) | 2007-05-30 | 2008-05-30 | Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica. |
Country Status (6)
Country | Link |
---|---|
US (1) | US8313770B2 (es) |
EP (1) | EP2164631A4 (es) |
JP (1) | JP2010529040A (es) |
CA (1) | CA2689101C (es) |
MX (1) | MX2009013019A (es) |
WO (1) | WO2008151071A1 (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2645855C (en) | 2006-03-16 | 2015-02-03 | Tris Pharma, Inc. | Modified release formulations containing drug-ion exchange resin complexes |
CN102123938A (zh) | 2007-09-06 | 2011-07-13 | 可口可乐公司 | 用于提供混合饮料分配器中的份量控制编程的系统和方法 |
CN101821193B (zh) | 2007-09-06 | 2015-04-01 | 可口可乐公司 | 监测和控制多种产品形成成分的分配的系统和方法 |
US20100273822A1 (en) * | 2009-04-22 | 2010-10-28 | William Wayne Howard | Immediate release compositions and methods for delivering drug formulations using strong acid ion exchange resins |
MX2012006320A (es) | 2009-12-02 | 2013-01-18 | Adamas Pharmaceuticals Inc | Composiciones de amantadina y metodos para su uso. |
US8470375B1 (en) | 2010-01-05 | 2013-06-25 | Neos Therapeutics, Lp | Method of formulating and designing liquid drug suspensions containing ion exchange resin particles |
US20130230587A1 (en) * | 2010-11-10 | 2013-09-05 | Rubicon Research Private Limited | Sustained release compositions |
US9339478B2 (en) * | 2011-02-04 | 2016-05-17 | Reckitt Benckiser Llc | Pharmaceutical formulation |
US8287903B2 (en) * | 2011-02-15 | 2012-10-16 | Tris Pharma Inc | Orally effective methylphenidate extended release powder and aqueous suspension product |
EP2508174A1 (en) * | 2011-04-06 | 2012-10-10 | Ljiljana Sovic Brkicic | Pharmaceutical composition |
US20130004586A1 (en) * | 2011-06-24 | 2013-01-03 | Vachon David J | Biologically Efficacious Compositions, Articles of Manufacture and Processes for Producing and/or Using Same |
WO2013003622A1 (en) | 2011-06-28 | 2013-01-03 | Neos Therapeutics, Lp | Dosage forms for oral administration and methods of treatment using the same |
CA2880456A1 (en) | 2012-08-15 | 2014-02-20 | Tris Pharma, Inc. | Methylphenidate extended release chewable tablet |
US20140122120A1 (en) * | 2012-10-30 | 2014-05-01 | Pacesetter, Inc. | Systems and methods for providing photo-based patient verification for use with implantable medical device programmers |
WO2014132163A1 (en) * | 2013-02-28 | 2014-09-04 | Pfizer Inc. | Enhanced stability of novel liquid compositions |
WO2014204933A1 (en) | 2013-06-17 | 2014-12-24 | Adamas Pharmaceuticals, Inc. | Amantadine compositions and methods of use |
US20170128379A1 (en) * | 2014-06-30 | 2017-05-11 | Rubicon Research Private Limited | Modified release pharmaceutical preparations |
CN107074672A (zh) * | 2014-10-01 | 2017-08-18 | 农作物增强公司 | 用于农业应用的农用化学品树脂酸盐 |
US11590228B1 (en) | 2015-09-08 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine compositions |
CA3022933A1 (en) * | 2016-05-03 | 2017-11-09 | Spectrix Therapeutics, LLC | Compositions and methods of providing thyroid hormone or analogs thereof |
CA3072764A1 (en) | 2017-08-24 | 2019-02-28 | Adamas Pharma, Llc | Amantadine compositions, preparations thereof, and methods of use |
US11590081B1 (en) | 2017-09-24 | 2023-02-28 | Tris Pharma, Inc | Extended release amphetamine tablets |
US11690840B2 (en) | 2017-10-09 | 2023-07-04 | Rhodes Pharmaceuticals L.P. | Pharmaceutical resinate compositions and methods of making and using thereof |
WO2019094292A1 (en) * | 2017-11-09 | 2019-05-16 | Spectrix Therapeutics, LLC | Compositions and methods of providing thyroid hormone of analogs thereof |
US11337919B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Modified release drug powder composition comprising gastro-retentive RAFT forming systems having trigger pulse drug release |
US11337920B2 (en) | 2017-12-18 | 2022-05-24 | Tris Pharma, Inc. | Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release |
WO2019126215A1 (en) | 2017-12-18 | 2019-06-27 | Tris Pharma, Inc. | Ghb pharmaceutical compositions comprising a floating interpenetrating polymer network forming system |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK79841C (da) * | 1952-08-04 | 1955-09-12 | Behringwerke Ag | Fremgangsmåde til fremstilling af stabile γ-globulinpræparater. |
US3173876A (en) * | 1960-05-27 | 1965-03-16 | John C Zobrist | Cleaning methods and compositions |
US3276586A (en) * | 1963-08-30 | 1966-10-04 | Rosaen Filter Co | Indicating means for fluid filters |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3541006A (en) * | 1968-07-03 | 1970-11-17 | Amicon Corp | Ultrafiltration process |
US3541005A (en) * | 1969-02-05 | 1970-11-17 | Amicon Corp | Continuous ultrafiltration of macromolecular solutions |
US4285987A (en) * | 1978-10-23 | 1981-08-25 | Alza Corporation | Process for manufacturing device with dispersion zone |
US4221778A (en) * | 1979-01-08 | 1980-09-09 | Pennwalt Corporation | Prolonged release pharmaceutical preparations |
AU565487B2 (en) * | 1983-09-16 | 1987-09-17 | Fisons Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
US4762709A (en) * | 1983-09-16 | 1988-08-09 | Pennwalt Corporation | Liquid prolonged release pharmaceutical formulations containing ionic constituents |
US4692462A (en) * | 1985-03-18 | 1987-09-08 | Menley & James Laboratories, Ltd. | Compositions and method of controlling transdermal penetration of topical and systemic agents |
US4999189A (en) * | 1988-11-14 | 1991-03-12 | Schering Corporation | Sustained release oral suspensions |
GB9005498D0 (en) * | 1990-03-12 | 1990-05-09 | Beecham Group Plc | Composition |
JP3207494B2 (ja) * | 1992-04-02 | 2001-09-10 | ロート製薬株式会社 | 水性懸濁製剤 |
SE505146C2 (sv) * | 1995-10-19 | 1997-06-30 | Biogram Ab | Partiklar för fördröjd frisättning |
US5980945A (en) * | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
US5980882A (en) * | 1997-04-16 | 1999-11-09 | Medeva Pharmaceuticals Manufacturing | Drug-resin complexes stabilized by chelating agents |
US6613358B2 (en) * | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
US7815937B2 (en) * | 1998-10-27 | 2010-10-19 | Biovail Laboratories International Srl | Quick dissolve compositions and tablets based thereon |
DE60232290D1 (de) * | 2001-04-09 | 2009-06-25 | Rohm & Haas | Kontrollierte Auflösung von Wirkstoffen |
JP4808405B2 (ja) * | 2002-11-26 | 2011-11-02 | ホ−レンベック ギャリ− ア−ル | 高度に水溶性の電解質薬剤のための水性徐放性ドラッグデリバリーシステム |
US20050232987A1 (en) * | 2004-03-12 | 2005-10-20 | Viswanathan Srinivasan | Dosage form containing a morphine derivative and another drug |
JP2008546835A (ja) * | 2005-06-28 | 2008-12-25 | ユ セ ベ ソシエテ アノニム | 複数の活性薬物−樹脂抱合体 |
US20070092553A1 (en) * | 2005-10-21 | 2007-04-26 | Pfab Lp | Compositions and methods of making rapidly dissolving lonically masked formulations |
-
2008
- 2008-05-30 JP JP2010510531A patent/JP2010529040A/ja active Pending
- 2008-05-30 WO PCT/US2008/065408 patent/WO2008151071A1/en active Application Filing
- 2008-05-30 EP EP08769926.0A patent/EP2164631A4/en not_active Withdrawn
- 2008-05-30 US US12/130,762 patent/US8313770B2/en active Active
- 2008-05-30 CA CA2689101A patent/CA2689101C/en active Active
- 2008-05-30 MX MX2009013019A patent/MX2009013019A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090011027A1 (en) | 2009-01-08 |
EP2164631A4 (en) | 2013-08-21 |
EP2164631A1 (en) | 2010-03-24 |
US8313770B2 (en) | 2012-11-20 |
CA2689101C (en) | 2013-01-22 |
WO2008151071A1 (en) | 2008-12-11 |
CA2689101A1 (en) | 2008-12-11 |
JP2010529040A (ja) | 2010-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2009013019A (es) | Modificacion de liberacion de farmaco en suspensiones de sistemas de resina ionica. | |
CY1122732T1 (el) | Συνθεσεις για αναπνευστικη χορηγηση δραστικων παραγοντων και συναφεις μεθοδοι και συστηματα | |
MX2014000141A (es) | Agentes de enlace a receptor de canabinoide, composiciones y metodos. | |
SG10201804552WA (en) | Nanoparticle compositions, formulations thereof, and uses therefor | |
EA201190295A1 (ru) | Композиции для дермальной доставки, содержащие комплексы активного агента с частицами фосфата кальция, и способы их применения | |
UA122868C2 (uk) | Тетрагідропіридо[3,4-в]індолові модулятори естрогенових рецепторів та їх застосування | |
PH12016500372A1 (en) | Pharmaceutical composition containing pyrimidine compound as active ingredient | |
MX2013002048A (es) | Conjugados, particulas, composiciones y metodos relacionados. | |
HK1153636A1 (en) | Ophthalmic devices for the controlled release of active agents | |
MX2015015589A (es) | Composiciones y metodos para el suministro de agentes activos hidrófobos. | |
MX2013008146A (es) | Mejoras en tecnologia de revestimiento. | |
MY161236A (en) | (pyridin-4-yl)benzylamides as allosteric modulators of alpha 7 nachr | |
SG182629A1 (en) | Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof | |
MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
MY166972A (en) | Transdermal delivery system containing galantamine or salts thereof | |
MX2012001693A (es) | Formulaciones estables no corrosivas para inhaladores presurizados de dosis medida. | |
EA200800464A1 (ru) | Фармацевтическая композиция, содержащая периндоприл или его соли | |
MX2009003815A (es) | Formulaciones farmaceuticas. | |
EA201890703A1 (ru) | Коллоидные частицы, предназначенные для применения в медицине | |
EP2568990A4 (en) | METHOD OF PRODUCING PLEURODESIS | |
MX357799B (es) | Nuevo sistema de liberación de proteínas hidrofóbicas. | |
GB201004677D0 (en) | New salt | |
CL2013000174A1 (es) | Deposito farmaceutico que comprende 5-fluoro-2-[[(1s)-1-(5-fluoro-2-piridil)etil]amino]-6-[(5-isopropoxi-1h-pirazol-3-il)amino]piridin-3-carbonitrilo y un polimero que se degrada para liberar el principio activo; su uso en la prevención o el tratamiento de osteoartritis. | |
WO2022146367A3 (en) | Nanocone clusters suitable for use as histotripsy agent | |
WO2012108794A3 (ru) | Производные 1,2,4-триазол-з-илтиогликолевой кислоты для применения в терапии |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |